Keene Wei
Chief Executive Officer Vitsgen
Serial entrepreneur, deeply engaged across the full chain of drug discovery, CMC & compliance, regulatory strategy and marketing;
Founded VitsGen in 2021, focusing on the development of targeted radionuclide drug conjugates (RDCs);
Founded Viwit in 2006, specializing in Boranes, Drug Substances and Drug Products, as well as new drug R&D and manufacturing ~ with three production sites and multiple products approved by US FDA and China NMPA;
Previously served as Research Scientist at Bristol-Myers Squibb and Director of the Chemistry PepTech Corporation (USA);
PhD Dartmouth College, BS Peking University.
Seminars
Wednesday 25th February 2026
Peptide-Based RDC Design to Achieve Target Molecule & Dosimetry Profile
1:15 pm
- Investigating strategies to design peptide-based radiopharmaceuticals that precisely bind desired molecular targets for improved therapeutic efficacy
- Understanding methods to predict and modulate radiation distribution, minimizing off-target exposure and enhancing safety
- Gaining insights into integrating design, preclinical evaluation, and dosimetry planning to streamline progression from concept to clinical application
New Company for 2026
